SUO 2022 - 23rd Annual Meeting of the Society of Urologic Oncology
Nov 30 - Dec 02, 2022 | San DiegoCAUS
LARVOL is not affiliated with 23rd Annual Meeting of the Society of Urologic Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 30 abstracts linked to Trials
GENOMIC CORRELATE ANALYSIS FROM BLASST-1 (BLADDER CANCER SIGNAL SEEKING TRIAL) OF NIVOLUMAB, GEMCITABINE AND CISPLTAIN IN PATIENTS WITH MIBC UNDERGOING CYSTECTOMY
THE USE OF 68GA-FAP-2286 PET IMAGING IN PATIENTS WITH LOCALIZED BLADDER CANCER
PHASE 1B UPDATE OF CELLO-1: SAFETY AND PRELIMINARY EFFICACY OF TAZEMETOSTAT IN COMBINATION WITH ABIRATERONE/PREDNISONE OR ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
INTERIM ANALYSIS OF PADRES (PRIOR AXITINIB AS A DETERMINANT OF OUTCOME OF RENAL SURGERY NCT03438708) CLINICAL TRIAL
External validation of a digital pathology-based AI model predicting metastasis and death in high and very high risk men on NRG/RTOG 9902 phase III trial
A Phase I Clinical Trial of Intravesical Chemoimmunotherapy with Alternating Gemcitabine and Bacillus Calmette-Guérin for Non-Muscle Invasive Bladder Cancer (NCT04179162)
A PHASE II CLINICAL TRIAL OF NEOADJUVANT SASANLIMAB AND STEREOTACTIC BODY RADIATION THERAPY AS AN IN SITU VACCINE FOR CISPLATIN-INELIGIBLE MUSCLE INVASIVE BLADDER CANCER (RADVACCINE)
A PHASE 1, OPEN-LABEL TRIAL TO DETERMINE FEASIBILITY AND SAFETY OF INTRAMURAL INJECTION OF BELZUPACAP SAROTALOCAN (AU-011) IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
THE IMPACT OF BLUE LIGHT CYSTOSCOPY ON TUMOR RECURRENCE IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED IN A REAL-WORLD SETTING
DIAGNOSTIC PERFORMANCE AND SAFETY OF 18F-rhPSMA-7.3 PET IN PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER: RESULTS FROM A PHASE 3, PROSPECTIVE, MULTICENTER STUDY (LIGHTHOUSE)
AMPLITUDE: NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE TO TREAT PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER AND DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE ALTERATIONS
PEMBROLIZUMAB IN PARTICIPANTS WITH BACILLUS CALMETTE-GUERIN–UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: 5-YEAR FOLLOW-UP FROM COHORT A OF THE PHASE 2 KEYNOTE-057 TRIAL
Phase 1a/b Safety Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (ADVANCED-1)
COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS AN ADJUVANT TREATMENT OF RENAL CELL CARCINOMA POST-NEPHRECTOMY IN THE UNITED STATES
EXPLORATION OF THE IMMUNE MICROENVIRONMENT WITHIN RENAL CELL CARCINOMA TUMOR THROMBI